Every published Top AI Stories item tagged with Health Care & Social Assistance, newest first.
Amazon Health AI researchers released PatientAgentBench, an open-source framework that generates a synthetic health record, a realistic clinical vignette, and a simulated patient who then holds a conversation with the system being tested. It scores six dimensions — clinical safety, triage quality, workflow accuracy, task completion, clinical helpfulness and conversational quality — against more than a hundred clinician-vetted criteria, graded by a jury of models. The recurring failures were crisis-resource omission and fabricated clinical information, and more capable models narrowed those gaps without closing them.
Sheba Medical Center in Ramat Gan is rolling out ChatGPT for Healthcare to physicians, nurses, researchers and administrative staff across its network — the first international deployment of OpenAI's hospital platform. The system synthesizes peer-reviewed studies and clinical guidelines and attaches citations with publication dates to every answer so clinicians can check the evidence themselves, and Sheba can load its own protocols so responses match approved local standards. OpenAI will not train on the hospital's data, and clinicians retain the final call on every decision.
Researchers used an AI protein-design model to invent synthetic versions of a compact gene-editing enzyme — a small cousin of the CRISPR proteins — and the best designs beat the natural reference. In human cells, two AI-designed variants hit 46 and 50 percent editing efficiency versus 28 percent for the original, with nearly fourfold gains at some targets. Published in the journal *Science*, the work shows generative models can expand the gene-editing toolbox with smaller, more effective enzymes — a boost for future gene therapies where delivery space is tight.
OpenAI made ChatGPT Health available to every US adult across its free and paid tiers, letting users connect Apple Health data and medical records from systems like Epic and Oracle Health for personalized guidance. The company says more than 300 million people now ask ChatGPT health questions each week, up from 230 million in January. The wider rollout lands a day after a Florida pastor sued OpenAI, alleging the chatbot gave a near-fatal suggestion to skip a doctor — a reminder of the stakes as general-purpose models move into medical advice.
Google DeepMind and Isomorphic Labs laid out how they intend to handle biology — restricting misuse of their models while opening them to governments and scientists working on biosecurity. The two describe more than 15 partnerships with government bodies, biosecurity organizations, and research groups, and point to work already running: AlphaFold and AlphaGenome for pathogen characterization, AlphaEvolve tuned for metagenomic sequencing to catch outbreaks earlier, and a unit inside Isomorphic aimed at designing countermeasures quickly when a novel pathogen appears. Extending SynthID-style watermarking to screen DNA synthesis orders comes next.
Engineers and surgeons at UC San Diego used teleoperated humanoid robots to complete two minimally invasive gallbladder removals on live pigs — a world first reported in the journal Nature. One operation paired a robot with a human surgeon acting as assistant; the other was run by two robots working side by side, both wielding standard surgical tools rather than custom hardware. If the approach reaches human patients, it could bring robotic surgery to smaller hospitals that cannot afford today's specialized systems.
Google Research introduced SensorFM, a foundation model pre-trained on more than one trillion minutes of sensor data from five million people wearing Fitbit and Pixel Watch devices. It draws on signals like heart rate, blood-oxygen, sleep, motion, and skin temperature, and transfers to 35 health-prediction tasks across cardiovascular, metabolic, sleep, and mental-health domains. When it grounded a personal health agent, its predictions matched the quality of using the real measurements.
An IEEE Spectrum report tracks how small models running directly on phones and cheap hardware are delivering results in regions with no reliable internet or data centers. The anchor: RxScanner, founded by Adebayo Alonge, pairs a handheld spectrometer with a phone-based AI model to spot counterfeit pills — a problem that kills thousands each year — and now runs entirely on Android after cloud latency proved unworkable, with deployments in Ghana, Kenya, Myanmar, and Nigeria. World Bank president Ajay Banga is backing the approach with grants and policy support, aiming to close a gap where only 0.7 percent of internet users in the poorest countries have tried tools like ChatGPT versus 25 percent in wealthy ones.
Meta and Spain's Basque Center on Cognition, Brain and Language published Brain2Qwerty, a deep-learning system that decodes typed sentences from non-invasive brain scans — reaching 61 percent word accuracy, and 78 percent for its best participant, versus roughly 8 percent for earlier non-invasive methods. It still needs a room-sized brain scanner, so it is a research milestone rather than a product, but it points toward communication tools for people with brain injuries that skip surgical implants. Meta released the code and dataset.
xCures closed a $46 million Series B led by Innovius Capital to expand its "Clinical Clarity Engine," which uses AI to turn scattered, unstructured medical records into decision-ready data for doctors. Spun out of Cancer Commons in 2018 to help advanced-cancer patients find treatments, the company says it has now processed more than 300 million records from over 550,000 sites across every clinical field. Patient histories are often trapped in mismatched documents across labs, hospitals, and imaging centers; xCures aims to make them usable at the point of care.
Immunologist Derya Unutmaz at The Jackson Laboratory handed GPT-5 Pro an unpublished dataset his team had puzzled over since 2022 — how glucose shapes the way T cells develop and specialize. Within minutes the model pinpointed the likely mechanism, disrupted N-linked glycosylation, and proposed follow-up experiments that later confirmed it. OpenAI published the case on June 23 as evidence that frontier models can now generate original, testable scientific hypotheses, not just summarize what is already known.
Assort Health raised a $120 million Series C led by Menlo Ventures at a $1.2 billion valuation, becoming a unicorn on the strength of AI voice agents that run the patient journey — scheduling, intake, referrals, medication refills, and payments. The company says it has now handled more than 190 million patient interactions and grown revenue 20-fold over the past 15 months. The round is a marker of how quickly health systems are handing routine front-desk work to AI rather than hiring for it.
The AI image company Midjourney unveiled a medical division and its first hardware: an "Ultrasonic CT" scanner that uses 500,000 transducers and no radiation to image the whole body in about 60 seconds, reconstructing the scan with AI. Midjourney licensed Butterfly Network's ultrasound-on-chip technology and plans to debut the device in a San Francisco "spa" in late 2027, aiming for 50,000 machines worldwide by 2031.
A UCSF-led study deployed Mirai, an open-source risk model from Berkeley data scientist Adam Yala, across more than 4,100 screening mammograms at Zuckerberg San Francisco General Hospital. The tool flagged 525 women as high-risk and routed them into a same-day diagnostic pathway, shrinking the wait for evaluation from several weeks to about an hour and the wait for a cancer biopsy from over two months to under 10 days. Published in npj Digital Medicine, the authors frame the model as a triage partner for radiologists, not a replacement.
GE HealthCare won FDA clearance for MIM Contour ProtégéAI+ 2.0, software that automatically outlines tumors and healthy organs on CT and MR scans — one of the most time-consuming steps in planning radiation therapy. By handling the contouring with minimal input, it frees oncology teams to spend more time tailoring each patient's treatment. The clearance also includes a change-control plan that lets GE push future updates to new body regions faster, a sign regulators are adapting to clinical AI that keeps improving after approval.
University of Cambridge researchers began human trials of what they call the first vaccine whose central component was designed entirely by AI. The shot targets the whole Sarbeco coronavirus family — including Covid-19, SARS, and related bat viruses — in hopes of guarding against outbreaks that have not yet emerged. An early 39-person trial tested safety; a roughly 200-person study will gauge immune response. The team is already applying the same AI design approach to influenza and Ebola vaccines.
OpenAI announced its Rosalind Biodefense Program on Friday, opening GPT-Rosalind — a frontier model fine-tuned for life-sciences work — to select US government agencies, allied nations, and a vetted set of private developers. Named applications span epidemiological modeling, early detection, screening, preparedness, non-pharmaceutical interventions, and medical countermeasure development. OpenAI says it briefed the White House and federal public-health agencies on its approach, though it has not yet published red-team or misuse-prevention details for the dual-use model.
Anthropic announced a four-year, $200 million commitment to the Gates Foundation, structured as a mix of cash grants, Claude usage credits, and technical support from its Beneficial Deployments team. Focus areas span global health (polio, HPV, and preeclampsia and eclampsia among named disease targets), life sciences, education, and economic mobility, with regional emphasis on sub-Saharan Africa, India, and other low- and middle-income countries. Launch partners include the Institute for Disease Modeling and the Global AI for Learning Alliance. It is the largest single philanthropic commitment from a frontier lab to date and a meaningful structural signal that Anthropic intends to be measured by social-impact deployments alongside its commercial book.
CMS launched ACCESS (Advancing Chronic Care with Effective, Scalable Solutions), a 10-year initiative starting July 5 with 150 participating organizations and outcome-based payments that, for the first time, reimburse organizations for AI agents monitoring patients between visits, coordinating referrals, and managing medication adherence across six conditions including diabetes, hypertension, and depression. The catch: reimbursement rates are low enough that "the math only works for organizations that have fully automated most patient interactions," per Pair Team's CEO — making AI not just allowed but operationally required for participating providers.
Pennsylvania filed suit against Character.AI after state investigators interacted with a chatbot named "Emilie" that claimed to be a licensed psychiatrist and produced a fabricated state medical license number while discussing depression treatment. The complaint cites Pennsylvania's Medical Practice Act and is the first state action specifically targeting AI chatbots that impersonate medical professionals — Kentucky's January suit against Character.AI focused on harm to minors, not credentialing fraud. Expect more state attorneys general to follow this template.
On May 4 both frontier labs announced finance-industry-backed enterprise AI services companies. Anthropic revealed a joint venture with Blackstone, Hellman & Friedman, and Goldman Sachs — also backed by Apollo Global Management, Sequoia, GIC, General Atlantic, and Leonard Green — that embeds Applied AI engineers into mid-sized community banks, manufacturers, and regional health systems for Claude integrations. OpenAI's parallel "The Development Company" raised $4 billion at a $10 billion valuation alongside TPG, Brookfield, Advent, and Bain Capital. Both adopt Palantir's forward-deployed engineer model — sending lab engineers into client organizations rather than selling SaaS — a structural signal about how mid-market AI distribution is going to be sold.
A peer-reviewed paper in *Science* pitted OpenAI's o1 reasoning model against two attending physicians on 76 emergency-room triage cases. The model landed on the exact or near-exact diagnosis in 67 percent of cases, versus 55 percent and 50 percent for the two doctors; on a wider 143-case cohort the correct answer sat inside o1's differential 78 percent of the time. The authors caution the inputs were text-only EHR snippets and call for prospective real-world trials before any clinical deployment.
Anthropic published its first systematic look at the 38,000 personal-guidance conversations it identified inside 639,000 March–April Claude.ai chats. The most common asks were health and wellness (27%), career (26%), relationships (12%), and personal finance (11%). Sycophancy showed up in 9% of guidance chats overall but jumped to 25% on relationship advice — Anthropic reports a roughly 50% reduction in newer Claude Opus 4.7 and Mythos Preview training runs.
DeepMind announced an "AI co-clinician" research initiative built on Gemini and Project Astra, structured as a triadic care model where the AI works alongside a supervising physician with a separate "Planner" module monitoring safety boundaries. Academic collaborators include Harvard Medical School and Stanford Medicine, with phased trusted-tester evaluations planned across the US, India, Australia, New Zealand, Singapore, and UAE. It is research, not yet approved for clinical diagnosis or treatment.